SequelSEC

Autolus Therapeutics plc AUTL

Biological Products, (No Diagnostic Substances) · CIK 0001730463 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$117.39M
Fiscal year ended 2026-06-30
Operating income
-$247.44M
Fiscal year ended 2026-06-30
Free cash flow
-$232.73M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$548.89MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$2.06Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue7.3×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity3.1×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Biological Products, (No Diagnostic Substances) filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Gross margin-27.8%2th
Revenue YoY growth644.9%95th
CapEx / revenue25.3%79th
Current ratio5.94x60th
R&D / revenue156.1%40th
FCF margin-401.4%41th
Net margin-381.4%47th
Operating margin-358.9%48th

Autolus Therapeutics plc (AUTL) reported revenue of $117.39M and net income of -$280.16M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Autolus Therapeutics plc’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Autolus Therapeutics plc income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$117.39M
Cost of revenue$99.01M
Gross profit$18.38M
Operating income-$247.44M
Net income-$280.16M
Research & development$112.63M
Weighted-average diluted sharesUnavailable
Pretax income-$279.48M
Income tax expense$677.00K
Diluted EPSUnavailable
Selling, general & administrative$153.19M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

Autolus Therapeutics plc balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$171.41M
Total assets$493.23M
Current assets$336.09M
Total liabilities$418.39M
Current liabilities$68.79M
Total equity incl. NCI$74.84M
Temporary (mezzanine) equityUnavailable
Inventory$33.43M
Accounts receivable$44.39M
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$1.37M

Cash flow

Autolus Therapeutics plc cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$225.61M
Capital expenditures$7.12M
Investing cash flow$286.14M
Financing cash flow-$7.77M
Net change in cash$47.58M
Stock-based compensationUnavailable
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$8.59M

Derived

Autolus Therapeutics plc derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$232.73M
Gross margin15.7%
Operating margin-210.8%
FCF margin-198.3%
SBC / revenueUnavailable
Current ratio4.89x
Revenue YoY growth292.2%
Net margin-238.7%
R&D / revenue95.9%
CapEx / revenue6.1%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open AUTL in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-11View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-27View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.